State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China.
Department of Internal Medicine, Ohio State University College of Medicine, USA.
Cytokine Growth Factor Rev. 2019 Dec;50:60-74. doi: 10.1016/j.cytogfr.2019.04.004. Epub 2019 Apr 3.
Autoimmune diseases (ADs), which are common immune-mediated inflammatory syndromes, are characterized by an imbalance between T effector (Th)1/Th17 cells and T regulatory cells. Interleukin (IL)-33, a member of the IL-1 family, induces inflammatory disease development by mediating type 2 immune responses. Recently, IL-33/ST2 axis was reported to induce autoimmunity involving Th1 and Th17 cells. In this review, we focus on the expression, regulation and function of IL-33/ST2 pathway in the context of autoimmune disorders. We discuss the clinical potential of this signaling pathway in predicting disease activity and severity and offer possible future therapeutic alternatives.
自身免疫性疾病（ADs）是常见的免疫介导的炎症综合征，其特征是 T 效应（Th）1/Th17 细胞与 T 调节细胞之间失衡。白细胞介素（IL）-33 是 IL-1 家族的成员，通过介导 2 型免疫反应诱导炎症性疾病的发展。最近，IL-33/ST2 轴被报道可诱导涉及 Th1 和 Th17 细胞的自身免疫。在这篇综述中，我们重点讨论了 IL-33/ST2 通路在自身免疫性疾病中的表达、调节和功能。我们讨论了该信号通路在预测疾病活动和严重程度方面的临床潜力，并提供了可能的未来治疗选择。
